Crescita Therapeutics Inc
TSX:CTX
Crescita Therapeutics Inc
TSX:CTX
Price:
0.5
CAD
-3.85%
Market Cap:
CA$9.3m
Relative Value
The Relative Value of one
CTX
stock under the Base Case scenario is
0.59
CAD.
Compared to the current market price of 0.5 CAD,
Crescita Therapeutics Inc
is
Undervalued by 16%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CTX
Relative Value
Base Case
0.59
CAD
Undervaluation 16%
Multiples Across Competitors
CTX Competitors Multiples
Crescita Therapeutics Inc Competitors
Crescita Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
|
Crescita Therapeutics Inc
TSX:CTX
|
9.3m CAD | 0.4 | 20.4 | 1.8 | -1.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD | 15.3 | 48.4 | 32.6 | 34.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
574.1B USD | 6.1 | 21.4 | 14.9 | 18.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
283.4B CHF | 4.6 | 30 | 12.7 | 14.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
296.9B USD | 4.5 | 16 | 10 | 11.7 | |
| CH |
|
Novartis AG
SIX:NOVN
|
231.1B CHF | 5.3 | 21.2 | 13.1 | 16.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.8B GBP | 5.1 | 31.7 | 15.1 | 22.2 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK | 4.6 | 13.8 | 10.1 | 11.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154B USD | 2.4 | 19.7 | 7.4 | 9.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
124B USD | 2.6 | 17.7 | 6.9 | 8.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
